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Candidemia has become the fourth most common bloodstream infection over the past two decades and is the leading cause of invasive fungal infections among 
hospitalized patients [1,2]. Fungal infections possess the second-
highest case fatality rate (13%) among all causes of sepsis in 
children [3]. Pediatric patients who are diagnosed with candidemia 
have higher rates of mortality, increased length of hospital stay 
and a mean increase in total per patient hospital charges [4]. The 
prevalence of infections caused by non-albicans Candida (NAC) 
species that may have less susceptibility to antifungal agents, has 
increased steadily, accounting for >50% episodes of candidemia 
in many surveys conducted in adults and children all over the 
world [5-9]. A myriad number of risk factors and predictors are 
associated with candidemia [10-17].
Only a few Indian studies have analyzed the cases of 
candidemia in pediatric patients prospectively. The primary 
objective of this study was to determine the predictors of 
candidemia in the pediatric population (0–12 years) admitted 
in a tertiary care hospital and the secondary objectives were to 
determine the clinical and microbiological profile and outcome of 
candidemia in these children.
MATERIALS AND METHODS
This is a prospective, hospital-based study over a period of 1 year 
performed in a tertiary care hospital in New Delhi. The study 
was conducted after obtaining Institutional Ethics Committee’s 
approval. The sample size was calculated taking the prevalence 
of suspected fungal sepsis among pediatric patients of 20% from 
the hospital registry. Children of 0–12 years with risk factors for 
fungal sepsis (which included prematurity, mechanical ventilation, 
urinary catheterization, recent surgery, and prolonged antibiotic 
therapy, hematological disorders, neutropenia, malnourishment, 
HIV-AIDS, prolonged steroid therapy, previous exposure to 
antifungals, and Candida isolation from sites other than blood or 
sterile body fluids) were tracked from the admission register of 
the wards. Patients with risk factors for fungal sepsis and who 
remained sick even after 72 h of treatment with broad-spectrum 
antibiotics or had strong suspicion of fungal sepsis based on their 
underlying disease condition were enrolled in the study after 
taking consent from the parents. Presenting clinical features and 
results of laboratory investigations (including serial hemograms, 
absolute neutrophil counts (ANCs), blood chemistries, liver and 
ABSTRACT
Background: Bloodstream infections due to Candida species are becoming a major cause of morbidity and mortality in hospitalized 
patients. The emergence of non-albicans Candida (NACs) species with lesser susceptibility to antifungals has added to the woes 
of clinicians. Objectives: The objectives of the study were to determine the clinical and laboratory predictors and microbiological 
profile of candidemia in pediatric patients. Materials and Methods: This is a hospital-based, prospective, and cross-sectional 
study conducted in the pediatric department of a tertiary care hospital. A total of 250 children aged 0–12 years with risk factors 
for fungal sepsis were enrolled. Demographic details, clinical, and laboratory parameters were noted and samples were sent for 
culture. Cultures yielding growth of Candida were included in the study, and antifungal susceptibility performed. Associations were 
assessed using Chi-square test first and then through logistic regression models. Results: Among the 250 patients with risk factors 
for fungal sepsis, 47 patients (18.8%) with culture proven candidemia were identified. Predictors of candidemia among neonates 
were prematurity (<30 weeks), prolonged ventilation (>72 h), and thrombocytopenia. Among pediatric patients, prolonged steroid 
intake, Candida isolation from sites other than blood and persistent neutropenia, were significantly associated with the candidemia. 
NAC species were the predominant isolates (78.7%). Conclusion: Candidemia should be suspected in premature neonates requiring 
prolonged ventilation with unexplained thrombocytopenia. Among pediatric patients, prolonged steroid intake, Candida isolation 
from sites other than blood and persistent neutropenia are predictors of candidemia.
Key words: Antifungals, Candidemia, Neonates, Predictors
Kumar et al. Candidemia in children
Vol 6 | Issue 9 | September 2019 Indian J Child Health 475
kidney function tests, Gram stain and culture from appropriate 
body fluids, and C-reactive protein only for neonates) were 
recorded serially.
Five ml blood sample was withdrawn from the enrolled patients 
under strict aseptic precautions in the biphasic medium using 
Brain Heart Infusion Agar and broth and sent for fungal blood 
culture. Other sterile fluids for fungal culture (e.g., cerebrospinal 
fluid [CSF], peritoneal or pericardial fluid) were sent in sterile 
culture bottles. Urine for fungal hyphae and culture was sent 
simultaneously with the fungal blood culture to assess Candida 
isolation from sites other than blood and sterile body fluids. 
Samples were processed the same day or if delay was anticipated 
then the samples were stored at 2–8°C. The biphasic medium 
was incubated at 37°C for 48 h. Candida growth was identified 
based on their morphology on Corn Meal Agar, HiCrome agar, 
germ tube test, and ascospore production on malt extract agar, 
growth at 42°C, and cycloheximide tolerance. In case of unusual 
isolates, DNA sequencing was done at Mycology Referral Centre, 
PGIMER, Chandigarh. Antifungal susceptibility testing was done 
by broth microdilution, and E-strip method and interpretation 
were done as per CLSI M27 A3, 2012, and CLSI M44A [18].
The diagnosis of candidemia was done as per the EORTC/
Mycoses Study Group consensus group criteria [19]. The 
consensus group defines proven invasive fungal disease (IFD) 
as the demonstration of fungal elements on histopathologic, 
cytopathologic, or direct microscopic examination of a biopsy 
specimen or recovery of fungal elements from the culture of blood 
or a sterile body fluid under proper sterile conditions. Probable 
IFD requires the presence of a host factor, a clinical criterion, 
and mycological evidence of fungal infection. Cases that meet 
the criteria for a host factor and a clinical criterion but for which 
mycological criterion are absent is considered possible IFD. (In 
this study, we have taken only proven cases of candidemia in 
whom a Candida species was isolated on culturing blood or a 
sterile body fluid obtained under aseptic precautions).
Children with risk factors for fungal sepsis and whose fungal 
culture revealed the growth of Candida species were taken as 
cases and children with risk factors for fungal sepsis but whose 
fungal culture showed no growth were taken as the control group. 
Children with risk factors for fungal sepsis and whose fungal 
culture revealed the growth of organisms other than Candida 
were excluded from the study.
The diagnosed cases were managed as per the existing standard 
unit policy, guided by the culture and sensitivity reports. Children 
were followed until discharge or death. Parameters of morbidity 
included starting of feeds after initiation of treatment (among 
neonates) and duration of stay in the hospital. The outcome was 
taken as whether the child got discharged or did not survive.
The diagnosed cases were analyzed for the underlying risk 
factors, presenting clinical features and laboratory outcomes, 
and the results were compared with the control group to assess 
the clinical and laboratory predictors of candidemia in pediatric 
patients. Since the clinical profile, risk factors and the laboratory 
studies done in the neonatal and pediatric groups were quite 
different, we analyzed the neonatal and pediatric groups, 
separately. There were a lot of confounding factors in predictors 
of candidemia, so we used logistic analysis to nullify the effect of 
confounding factors among the predictors of candidemia.
Chi-square test was used to determine the association of 
clinical features, lab parameters, and risk factors between 
candidemia patients and non-candidemia patients. Multiple 
logistic regression models were used to test these associations 
adjusting for all other variables that may work as confounding 
factors. The results were considered significant at 5% level of 
significance. All the analyses were done using statistical software 
SPSS 17.0.
RESULTS
During the study period, 302 children aged 0–12 years having risk 
factors for fungal sepsis and meeting the inclusion criteria were 
enrolled in the study. Out of these, 52 children were excluded 
from the study as 7 children grew fungi other than Candida 
Table 1: Bivariate and multivariate association between risk 
factors and candidemia in neonates
Variables Crude 
OR (95% CI)
p values Adjusted 
OR (95% CI)
p value
Prematurity (<37 weeks)
<30 Reference - Reference
30–34 0.2 
(0.07–0.64)
0.006 0.13 
(0.03–0.6)
0.009
34–37 - - - -
Mechanical ventilation
None Reference Reference
<72 h 0.78 
(0.19–3.25)
0.737 0.25 
(0.02–2.54)
0.239
>72 h 6.47 
(1.92–21.75)
0.003 8.62 
(1.91–39)
0.005
Neutropenia
No Reference Reference
Yes 1.16 
(0.29–4.7)
0.83 2.91 
(0.45-18.78)
0.262
Prolonged antibiotic therapy
None Reference Reference
<72 h 0.85 
(0.22–3.24)
0.808 -
>72 h - - -
Recent surgery (within last 2 weeks)
No Reference Reference
Yes - - - -
Urinary catheterization
None Reference Reference
>72 h - - 0.00 
(0.00–0.00)
0.999
Candida isolation from other sites
No Reference Reference
Yes - - 0.00 
(0.00–0.00)
0.998
OR: Odds ratio, CI: Confidence interval
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species in their fungal blood culture (1 Histoplasma spp., 3 
Trichosporon spp., and 3 Aspergillus spp.), and the rest had 
incomplete data or they left against medical advice. Hence, a total 
of 250 children were analyzed in our study.
Among the 250 patients, 47 patients (18.8%) with culture 
proven candidemia caused by a single species were identified 
as cases, and the rest 203 were in the control group. Among 
these, 43 cases grew Candida spp. in blood while the rest grew 
Candida spp. in sterile body fluids (1 in CSF, 1 in pericardial 
fluid, and 2 in peritoneal fluid).
Of the total 250 children analyzed in the study, 57.6% of 
children were males. There were 38.4% neonates (<1 month) 
and rest were pediatric patients (1 month–12 years). The median 
postnatal age of the neonates was 21 days while the median age 
of pediatric patients was 5 years. The mean gestational age of 
neonatal patients was 31.2±2.1 weeks, and the mean birth weight 
was 1.25±0.24 kg.
The case and control groups were matched for age and sex. 
However, there was a significant difference in the mean gestational 
age and birth weight in the two groups among neonates. The 
mean gestational age was 29.85±1.53 weeks among cases and 
31.5±2.11 weeks among controls (p<0.05). Similarly, the mean 
birth weight was 1.12±0.16 kg and 1.28±0.25 kg among cases and 
controls, respectively (p<0.05).
More than one-third of patients were neonates with sepsis 
and meningitis. The next largest group was of patients with 
hematological disorders (ALL and other hematological 
malignancies and aplastic anemia), who accounted for 18.4% 
(n=46) of the study population. Other patients enrolled were 
having pyrexia of unknown origin/septicemia (32, 12.8%), 
Table 2: Bivariate and multivariate association between laboratory parameters and candidemia among neonates
Variables Crude OR (95% CI) p value Adjusted OR (95% CI) p value
Absolute neutrophil count 1
>1500/mm3 Reference Reference
1000–1500/mm3 1.37 (0.13–14.03) 0.789 - -
500–1000/mm3 1.37 (0.13–14.03) 0.789 - -
<500/mm3 - - - -
Absolute neutrophil count 2
>1500/mm3 Reference Reference
1000–1500/mm3 - - - -
500–1000/mm3 1.5 (0.36–6.3) 0.58 - -
<500/mm3 4 (0.24–67.47) 0.336 - -
Absolute neutrophil count 3
>1500/mm3 Reference Reference
1000–1500/mm3 3.09 (0.63–15.22) 0.165 - -
500–1000/mm3 - - - -
<500/mm3 2.06 (0.18–24.18) 0.564 - -
Liver function tests
N Reference Reference
abN - - - -
Kidney function tests
N Reference Reference
abN 1.3 (0.24–6.97) 0.762 - 0.996
Serum electrolytes
N Reference Reference
abN 4.11 (0.54–31.19) 0.172 95,000,000 (0–0) 0.995
Platelet count
N for age Reference Reference
↓ for age 2.85 (1.02–7.96) 0.046 4.47 (0.96–20.76) 0.056
C-reactive protein
NA Reference Reference
Negative 0.55 (0.07–4.56) 0.576 0.63 (0.1–3.89) 0.617
Positive 0.49 (0.08–2.94) 0.437 - -
CSF study
NA Reference Reference
N 0.36 (0.06–2.35) 0.289 0.44 (0.02–10.28) 0.612
abN 0.5 (0.03–8.95) 0.638 - -
CSF: Cerebrospinal fluid, OR: Odds ratio, CI: Confidence interval
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protein-energy malnutrition (24, 9.6%), nephrotic syndrome (19, 
7.6%), primary immunodeficiency or HIV-AIDS (4, 1.6%), post-
surgical cases (4, 1.6%), and others (26, 10.4%). No significant 
association was seen between cases of candidemia and the 
underlying diseases. Similarly, there was no significant difference 
in the clinical presentation of the case and control groups in both 
neonatal and pediatric populations.
Among the risk factors, 100% neonates were premature. 
About 43.75% neonates required ventilation (26.04% required 
ventilation <72 h while 17.7% required ventilation >72 h). 
Neutropenia was present in 13.54% neonates. About 93.75% 
neonates had received prolonged antibiotics >72 h, but none 
were exposed to antifungals, previously. Only 5.2% neonates had 
history of recent surgery, and only 4.1% were catheterized for 
>72 h. Candida was isolated from a site other than blood or sterile 
body fluids in 5.2% neonates.
Among neonates, in multivariate logistic regression analysis, 
only extreme prematurity (gestation <30 week) and prolonged 
ventilation (>72 h) were significantly associated with the study 
group (Table 1). Neonates who were 30–34 weeks premature 
were 87% less likely to be in the study group than neonates who 
were <30 weeks premature (odds ratio [OR]=0.13, p=0.009). 
Similarly, neonates with >72 h ventilation were 8.62 times more 
likely to be in the study group than neonates with no ventilation 
(OR=8.62, p=0.009).
Among the lab parameters, only thrombocytopenia had a 
significant association with candidemia in neonates (Table 2). 
Platelet count reduced for age was present in 65% of neonates 
in the case group as compared to 39.5% neonates in the control 
group (p<0.05). In multiple logistic regression, this association 
also lost the significance (p=0.056), though the neonates with 
decreased platelet count were 4.47 times more likely to be in 
the case group (OR=4.47) than the neonates with normal for age 
platelet counts after adjusting other laboratory parameters.
In pediatric patients, among the risk factors, mechanical 
ventilation was required in 13.6%, the hematological abnormality 
was present in 31.2% patients while neutropenia was present in 
33.1% of patients. About 32.5% of patients were malnourished, 
20.7% of patients had history of prolonged steroid intake, and 
75.3% of patients had received antibiotics for >72 h. About 15.6% 
of patients were previously exposed to antifungals. HIV-AIDS 
was present in 1.3% patients, 1.95% of patients had a history 
of recent surgery and 5.2% of patients had history of urinary 
catheterization for >72 h. Candida was isolated from sites other 
than blood or sterile body fluids in 22.72% patients.
After adjusting for all the confounding factors only prolonged 
steroid use (>2 weeks) and Candida isolation from a site other 
than blood or sterile body fluids were (Table 3) significantly 
associated with candidemia in pediatric patients. Pediatric 
patients with prolonged steroid use were 5.91 times more likely to 
be in the study group after adjusting other risk factors (OR=5.91, 
p=0.011). Furthermore, pediatric patients with Candida isolation 
from other sites were 11.92 times more likely to be in the study 
Table 3: Bivariate and multivariate association between 
risk factors and candidemia among pediatric patients
Variables Crude OR 
(95% CI)
p values Adjusted OR 
(95% CI)
p value
Mechanical ventilation
Others Reference Reference
<72 h - - - -
>72 h 1.7 
(0.42–6.9)
0.456 9664.09 
(4.68–20,000,000)
0.018
Hematological disorders
No Reference Reference
Yes 2.44 
(1.04–5.71)
0.039 33.61 
(0.5–2279.23)
0.102
Neutropenia
No Reference Reference
Yes 2.17 
(0.93–5.06)
0.072 0.07 
(0–5.64)
0.233
Malnourishment
None Reference Reference
Moderate 0.3 
(0.04–2.45)
0.263 0.06 
(0–2.04)
0.119
Severe 0.52 
(0.14–1.87)
0.314 0.69 
(0.1–4.86)
0.713
Prolonged steroids (>2 weeks)
None Reference Reference
Yes 2.26 
(0.9–5.67)
0.082 5.91 
(1.5–23.26)
0.011
Prolonged antibiotics therapy
None Reference Reference
<72 h - 1 (0–0) 0
>72 h 0.69 
(0.13–3.75)
0.665 3.29 
(0.13–84.9)
0.472
Previous antifungal therapy
No Reference Reference
Yes 4.75 
(1.82–12.38)
0.001 3.87 
(0.92–16.38)
0.066
Recent surgery (within past 2 weeks)
No Reference Reference
Yes 10.08 
(0.88–115.48)
0.063 8.89 
(0.42–188.88)
0.161
Urinary catheterization
None Reference Reference
<72 h 0.65 
(0.08–5.49)
0.689 0.01 
(0–1.44)
0.071
>72 h 0.65 
(0.08–5.49)
0.689 0.0004 
(0–1.07)
0.052
HIV-AIDS
No Reference Reference
Yes - - - -
Candida isolation from other site
No Reference Reference
Yes 3.62 
(1.5–8.75)
0.004 11.92 
(2.84–50)
0.001
OR: Odds ratio, CI: Confidence interval
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group (OR=11.92, p=0.001). Although prolonged ventilation was 
also significantly associated with the study group (p=0.018), the 
OR was not reliable (OR=9664).
Among laboratory parameters, ANC <1500/mm3 was 
significantly associated with candidemia in pediatric patients. 
Pediatric patients with 500–1000/mm3 value in ANC1 were 
4.72 times more likely to be in the case group than the pediatric 
patients with >1500/mm3 (p=0.004). Furthermore, pediatric 
patients with <500/mm3 value in ANC2 were significantly 
3.55 times more likely to be in the case group than the neonates 
with >1500/mm3 (p=0.008). In multiple logistic regression 
analysis however these associations lapsed due to not having 
sufficient values to estimate ORs.
The species of Candida growth among cases of prevalence 
are shown in Fig. 1. Candida parapsilosis was the most common 
species among neonates (13 out of 20, 65%) and Candida 
tropicalis was the most common species among pediatric cases 
(10 out of 27, 37%).
A total of 36% of patients that were enrolled in the study died 
while rest were discharged. Mortality among the candidemia 
cases was 42.6% while the rest 57.4% were discharged. Similarly, 
among the control group, 34.5% of patients died while 65.5% 
were discharged. However, no significant difference was seen 
between the cases and controls with respect to outcome in terms 
of discharge or death.
DISCUSSION
The species distribution of Candida species among study cohort 
showed that Candida albicans constituted 21.3% of cases while 
NACs constituted 78.7% cases. This was in accordance with 
recent studies in Indian setups which also confirmed a similar 
predominance of NACs with isolation rates ranging from 66% to 
90% [20-23].
The most frequent isolate in our study was C. parapsilosis 
(29.8%) which was predominantly found among neonatal 
cases. Xess et al. [24] also found a shift of predominant species 
to C. parapsilosis in patients of all ages. This advent of C. 
parapsilosis in neonatal cases in India is alarming as it is an 
exogenous pathogen that may be found on the skin and is quite 
notorious for the ability to form biofilm on catheters and other 
implanted devices, for nosocomial spread by hand carriage, and 
for persistence in the hospital environment [25]. Most of the 
infections are acquired in association with intravascular catheters 
and parenteral nutrition. Thus, the detection of C. parapsilosis 
BSI should be a “red flag” regarding breaks in catheter care and 
infection control procedures.
In the present study, the sensitivity pattern of the growths 
revealed that fluconazole resistance was seen in 44.68% cases, 
and amphotericin-B resistance was seen in 14.9% cases, and 
only one isolate was resistant to voriconazole (Table 4). While 
most of C. albicans (70%) and C. parapsilosis (78.57%) isolates 
were sensitive to fluconazole, fluconazole sensitivity was only 
54.54% among C. tropicalis isolates and only 28.6% among 
Candida glabrata spp. This was in contrast to the previous 
study conducted in the year 2004 in the same hospital by 
Capoor et al. [18] that showed only 4.9% and 6.9% resistance 
to fluconazole and amphotericin-B, respectively. This increase in 
resistance to fluconazole and amphotericin-B might be explained 
by the changes in the treatment policy of the hospital where use of 
antifungal prophylaxis in children of hematological malignancies 
with febrile neutropenia has increased rampantly.
The study shows that neonates with gestational age <30 weeks 
were more likely to have candidemia as compared to neonates with 
30–34 weeks. Furthermore, neonates with prolonged ventilation 
(>72 h) were more likely to have candidemia as compared to the 
reference population with no mechanical ventilation. Similar 
results were found in many studies in Indian setups as well as 
Table 4: Species wise sensitivity pattern
Species (total no of isolates) A F V
N % N % N %
Candida albicans (10) 10 100 7 70 10 100
Candida parapsilosis (14) 14 100 11 78.57 14 100
Candida tropicalis (11) 10 90.9 6 54.54 10 90.9
Candida glabrata (7) 4 57.1 2 28.6 7 100
Candida krusei (2) 2 100 0 0 2 100
Candida guilliermondii (1) 0 0 0 0 1 100
Candida auris (2) 0 0 0 0 2 100
A=Amphotericin B, F=Fluconazole, V=Voriconazole
Figure 1: Candida species isolated in the study population
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abroad [26-28]. Extreme prematurity is a well-established risk 
factor for candidemia. The immature immune system, higher 
mean intensive care unit stay with exposure to nosocomial fungal 
infections, increased requirement of invasive procedures such as 
mechanical ventilation, central and peripheral venous lines, and 
prolonged total parenteral nutrition, and antibiotic requirement 
all might contribute to increased risk of candidemia in premature 
neonates.
Among laboratory parameters, thrombocytopenia emerged 
as the major laboratory predictor in neonates. It is a well-known 
concept that preterm babies with low birth weight have a limited 
response to thrombocytopenia in terms of platelet production 
and thrombopoietin [29]. This response might become limited 
during an episode of sepsis where the host has decreased energy 
reserves and possibly hepatic injury [30]. Many studies have been 
done among neonates to study the association between neonatal 
sepsis and platelet count, and it was found that the incidence of 
thrombocytopenia was highest among cases of fungemia and 
these cases were associated with greater decrease in platelet 
count from the baseline as compared to Gram-positive and 
Gram-negative sepsis [31]. Bhat et al. showed the association 
of thrombocytopenia with Gram-negative sepsis and candidemia 
and concluded that mortality increased in the group of neonates 
with candidemia and thrombocytopenia as compared to neonates 
with candidemia but no thrombocytopenia (36% vs. 16%) [32]. 
Thus, unexplained thrombocytopenia in preterm neonates with 
sepsis should raise the suspicion of candidemia, and the neonate 
should be aggressively investigated and managed for the same as 
the outcome might be poorer.
Candida isolation from sites other than blood and sterile body 
fluids, which has an adjusted OR of 11.92 (p=0.001) emerged as 
a strong predictor of candidemia in pediatric patients. Although 
we only screened urine for fungal hyphae and Candida species 
growth and in rare cases skin scrapings, endotracheal secretions 
or sputum for Candida isolation from other sites, the results were 
quite significant. Urine culture reports from candidemia cases 
showed that 29.6% (8 out of 27) pediatric cases of candidemia 
had simultaneous candiduria. The overall incidence of candiduria 
among candidemia cases was 21.27%. Chakrabarti et al. had a 
similar observation in their study where they found that candiduria 
was more likely a predictor of disseminated infection in patients 
having non-albicans candidemia [33].
Furthermore, prolonged steroid use (>2 weeks) emerged as a 
major risk factor among pediatric patients with an adjusted OR of 
5.91 (p=0.011). Prolonged steroid use (>2 mg/kg/day for >2 weeks) 
is an established risk factor for candidemia in adults [34].
The results of the bivariate analysis showed that patients 
with hematological disorders were 2.44 times more likely to 
be associated with candidemia (p=0.039). Similarly, patients 
with previous exposure to antifungal treatment were 4.75 times 
more likely to have candidemia (p=0.004). However, they lost 
their significance on adjusting for other confounding factors in 
multivariate analysis. Although these are established risk factors 
for candidemia, caution must be exercised while declaring them 
as predictors of candidemia because of the increased chances of 
bias. The demographic profile of our study population showed 
that the most predominant group among pediatric patients 
is of hematological disorders, many of whom are started on 
prophylactic antifungal therapy in view of their neutropenic 
status. Thus, further studies with appropriately matched study 
cohorts and larger sample size are required to explore their role as 
predictors of candidemia.
Among pediatric patients, low ANC came out as the most 
significant laboratory predictor of candidemia. Neutropenia is a 
well-established risk factor of candidemia [35]. Blyth et al. in 
their study found that among cases of candidemia, children were 
more likely to have neutropenia as compared to neonates and 
adults [27].
The outcome in the present study was measured in terms 
of duration of hospital stay and mortality, and no significant 
difference was seen among the case and control groups with 
regard to these measures. Mortality was comparable in both 
the groups (34.5% in candidemia cases and 42.6% in control 
patients). In this study, mortality attributable to candidemia 
could not be found as there are no clear cut measures to attribute 
the mortality to candidemia and also because of the serious 
underlying disease process in both case and control groups which 
might have confounded the outcome. Thus, it is only by matched 
cohort studies we can study the excess mortality and morbidity 
attributable to candidemia.
CONCLUSION
In this study, it was inferred that extreme prematurity (<30 weeks), 
prolonged ventilation (>72 h), and thrombocytopenia are strong 
predictors for candidemia in neonates while prolonged steroid 
intake (>14 days), Candida isolation from sites other than 
blood, and neutropenia (ANC<1000) are strong predictors for 
candidemia in pediatric patients in our setup.
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